We previously reported that Indian paediatric patients with atypical haemolytic-uraemic syndrome (aHUS) showed high frequencies of anticomplement factor H (FH) autoantibodies that are correlated with homozygous deletion of the genes for FH-related proteins 1 and 3 (FHR1 and FHR3) (FHR1/3 -/- 
Introduction
Among the categories of haemolytic-uraemic syndrome (HUS) identified, apart from secondary HUS, are the bacterial Shiga-like toxin (SLT) -associated forms and the 'atypical' (aHUS) forms 1, 2 in which disturbances of the complement pathway feature prominently. [3] [4] [5] Many mutations in complement pathway-related genes such as factor H (FH), FH-related proteins (FHRs), factor I, CD46, factor B and C3 have been reported to be associated with aHUS, especially in children. 3 In many reported series of paediatric aHUS, autoantibodies directed against FH have been identified and implicated in pathogenesis, 6, 7 and the therapeutic utility of immunosuppression and plasma exchange has been shown. 8, 9 Notably, the majority of aHUS patients with anti-FH autoantibodies have a deletion of the genes for the FH-related proteins 1 and 3 (FHR1 and FHR3), commonly as the result of being homozygous for a widespread~83-kb deletion encompassing the FHR1-FHR3 genes at chromosome 1q32. 10 Anti-FH autoantibody levels in aHUS are negatively correlated with clinical outcome. 11 They are primarily of the IgG3 isotype, 12 and are thought to be mostly directed at the C-terminal cell-surface anchorage-related region of FH, [13] [14] [15] [16] although greater epitope diversity has also been reported. 17, 18 FH is a negative regulator of complement activation, and there is evidence from mouse models that specific abrogation of FH functions at cell surfaces by inhibiting its cell-binding, with preservation of its fluidphase functions, leading to the typical histopathology of HUS. 19 The mechanism by which the FHR1-FHR3 deletion predisposes children to anti-FH autoantibody formation is unknown. FHR proteins appear to exist as homo-and hetero-dimeric species in which FHR1 is prominent, and competitively inhibit FH binding to cell surfaces. 20 There is also some evidence that FH and the FHRs can preferentially inhibit different steps of the complement cascade. 21 What role, if any, these FHR properties have on the levels and characteristics of anti-FH autoantibodies generated in children homozygous for the FHR1-FHR3 deletion is currently unclear.
Paediatric aHUS patients with anti-FH autoantibodies typically do not show the presence of other autoantibodies, 11, 22 suggesting an antigen-specific break in immune tolerance. However, the FHR1-FHR3 deletion has also been reported to be associated with increased risk of systemic lupus erythematosus, 15, 23 and with decreased risks for age-related macular degeneration and IgA nephropathy, 24, 25 possibly indicating more global immune function alterations, although these remain uncharacterized.
On this background, we have begun to examine a number of these poorly understood issues. Using an Indian paediatric aHUS series showing high frequency of anti-FH autoantibodies and associated FHR1-FHR3 deletion, 8 we report data here suggesting that the permissive role of the FHR1-FHR3 deletion in aHUS may not be restricted to anti-FH autoantibody generation, that anti-FH autoantibodies show variable avidity correlated with their levels but are epitopically restricted, and that patients with or without the FHR1-FHR3 deletion have similar properties of their anti-FH autoantibodies. Together, our data provide insights into the complexity of interactions between FHR1-FHR3 deletion, immunomodulation and anti-FH autoantibodies in aHUS.
Materials and methods

Patients and healthy volunteers
Patients below 18 years of age with suspected aHUS in the absence of diarrhoeal prodrome in the preceding fortnight from centres across India were included from 2007 onwards. HUS was diagnosed in the presence of acute kidney injury, anaemia with schistocytes, thrombocytopenia and high serum levels of lactate dehydrogenase. 5, 26 Patients with features of thrombotic microangiopathy secondary to human immunodeficiency virus, septicaemia, disseminated intravascular coagulation and systemic lupus erythematosus were excluded. Blood was collected from an antecubital vein into heparinized tubes and plasma and cells were separated. Cells were centrifuged on a Ficoll-Hypaque gradient, peripheral blood mononuclear cells were separated, and cells and DNA were stored at À80°until assay.
All work was reviewed and approved by the institutional human ethics committees of the relevant participating institutions, and informed consent for all participants was obtained.
DNA purification, multiple ligation-dependent probe amplification and real-time quantitative PCR assays Genomic DNA was extracted from peripheral blood mononuclear cells (Qiagen, Hilden, Germany) and purified (Genomic DNA isolation kit; Advanced Microdevices, Ambala, India) using commercial reagents. An appropriate commercial multiple ligation-dependent probe amplification (MLPA) assay was used for the estimation of heterozygous and homozygous deletions of FHR1 and FHR3 genes according to the manufacturers' instructions using SALSA MLPA probe mix P236-A2 ARMD mix 1 (lot 1109) and probe mix P236-A3 ARMD mix 1 (lot 0811) (MRC-Holland, Amsterdam, the Netherlands), using 125 ng of denatured genomic DNA for each reaction and sequencespecific probes for exons of FH. The FHR3, FHR1, FHR2 and FHR5 genes were used for PCR amplification, followed by analysis on a capillary electrophoresis system (ABI PRISM 3130 Genetic analyser), and calculation of relative peak heights and areas for each target (Coffalyser, MRCHolland) with normalization using known samples and identification of peak heights or areas between 40 and 70% as heterozygous deletion genotypes. 8 For real-time quantitative PCR assays, intron-3 genomic regions in both FHR1 and FHR3 loci 27 were amplified (Power SYBR Green PCR Master Mix; AB Systems, Waltham, MA) and 0Á2 lM of the indicated primers with requisite Taq DNA polymerase, reaction buffer (New England Biolabs, Ipswich, MA), magnesium chloride and dNTPs (Promega, Madison, WI). The assay was performed using a real-time PCR system (Eppendorf Mastercycler ep realplex 4). Cycle parameters: initial denaturation at 95°, 10 min, followed by 40 cycles of 15 seconds denaturation at 95°, 30 seconds annealing at 66°(FHR1) or 68°(FHR3) or 61°(BETA-ACTIN) followed by 30 seconds extension at 66°(final extension, 7 min). 27 All reactions were performed in triplicates. The values obtained for FHR1 and FHR3 gene copy numbers were normalized to the endogenous control gene beta actin and quantified relative to the copy number of control samples using the DDCT method. 28 Primers used 27 :
0 -AGCAGCCGTGGCCATCTCTT-3 0 . Conventional in-gel PCR assays were also performed (Veriti 96-well Thermal cycler, Applied Biosystems, Foster City, CA) with the same primers and conditions to ensure that amplified DNA bands of expected sizes could be detected. PCR products were run on 2Á5% agarose gel electrophoresis. Predicted sizes were 100 bp, 120 bp and 150 bp for the FHR1, FHR3 and BETA-ACTIN genes, respectively.
Cloning, expression and purification of FH truncation mutants
The construction of FH truncation mutants [short conservative region 1-4 (SCR1-4), SCR5-8, SCR9-12, SCR13-16 and SCR17-20] was achieved by PCR amplification of the required domains from the FH cDNA (OriGene, Rockville, MD) and cloning of these amplicons into pET28 or pET29 vectors. The SCR1-4, SCR5-8, SCR9-12 and SCR13-16 constructs were cloned in pET 28 at the NcoI and XhoI sites, whereas the SCR17-20 construct was cloned in pET 29 at the NdeI and XhoI sites. The primers were designed so that each mutant started with the first Cys of the starting domain (except for SCR1-4, which started with Glu) and ended with the last residue of the interdomain linker. The clones generated were verified by DNA sequencing (ABI 3730 DNA analyzer; Applied Biosystems). Appropriate primer sets were used for PCR amplification of the CCP domain regions (see Supplementary material, Table S1 ). Expression of all the truncation mutants was accomplished by transformation of the clones into Escherichia coli BL21 cells and induction of expression with 1 mM isopropyl 1-thio-b-D-galactopyranoside as detailed elsewhere. 29, 30 All expressed truncation mutants were found in inclusion bodies, and were purified as described earlier 29, 31 using Ni-NTA resin (Qiagen) in the presence of urea followed by elution with imidazole. The eluted mutants were then refolded by the rapid dilution method 32 and further purified on Superose12 gel filtration columns (Pharmacia, Stockholm, Sweden) to obtain the monodisperse species, confirmed as > 95% pure by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (see Supplementary material, Fig. S1 ).
Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assay (ELISA) plates (Microlon high-binding flat-bottomed 96-well plates; Greiner, Bahlingen, Germany) were coated with FH from human plasma (0Á5 lg/ml; Sigma-Aldrich, St Louis, MO), blocked, serum-titrated (1 : 100-1 : 100 000) and bound antibodies were detected with peroxidase-conjugated goat anti-human IgG (Sigma-Aldrich) followed by o-phenylenediamine dihydrochloride (Sigma-Aldrich), and colour read and analysed (Tecan microplate reader, Magellan software). A reference patient serum pool was used to calibrate the assay and to calculate anti-FH autoantibody concentrations in arbitrary units (AU)/ml (for examples, see Supplementary material, Fig. S2 ). 33 The reference serum pool used for quantification was calibrated with the Dragon-Durey laboratory reference standard widely described in the literature. 33 The detection limit was 200 AU/ml.
Relative avidities and epitope specificities of anti-FH autoantibodies were examined by using titrating concentrations of either native FH protein or various recombinant FH fragments to inhibit antibody binding to plate-coated native FH. Serum dilutions that gave detectable but submaximal binding to native FH were determined for each serum sample, were mixed with various inhibitor concentrations and added to FH-coated plates for ELISAs. The extent of inhibition was estimated, and 50% inhibitory concentrations were calculated where indicated.
The FH-SCR17-20 fragment was used to coat plates instead of native FH protein where indicated.
To detect FH-containing immune complexes, plates were coated with 2 lg/ml of mouse anti-human complement factor H monoclonal antibody (MCA509G 34 ; AbD Serotec, Hercules, CA), or, in a few assays, polyclonal anti-FH antibody (Bio-Rad, Hercules, CA). Control and test sera were titrated as shown, and bound FH-containing immune complexes were specifically detected using peroxidase-conjugated monoclonal mouse antihuman IgG (05-4220; Invitrogen, Calrsbad, CA) or polyclonal anti-human IgG (Sigma).
Statistical analysis
Comparisons were performed using, where appropriate as indicated, analysis of variance, the Mann-Whitney U-test with no assumption of normality, or a two-tailed Student's t-test with unequal variance, as appropriate, and a P-value of < 0Á05 was considered significant.
Results
Multiple ligation-dependent probe amplification, quantitative PCR and end-point PCR assays for detection of FHR1 and FHR3 gene deletions We next compared the MLPA, the qPCR and the endpoint PCR assays in DNA samples of aHUS patients and family members (n = 143) for consistency in detecting the FHR1 and FHR3 genotype. Almost all instances of homozygous FHR1 and FHR3 deletion were detected with complete concordance in all three methods, and heterozygous FHR1 and FHR3 deletions were also detected with substantial accuracy by the qPCR assays (Table 1) .
When we tested another set of 357 healthy human blood donor samples, we found 35 (9Á8%) to be of the À/À genotype, confirming our earlier report of presence in the asymptomatic Indian population at a frequency similar to that reported elsewhere. 8 
High frequencies of FHR1 and FHR3 gene deletions in anti-FH autoantibody-based aHUS categories
The bulk of the association between aHUS and the FHR1 and FHR3 deletion-homozygous genotype has been shown to be in the group of aHUS patients bearing anti-FH autoantibodies. 6, 35 However, most of these patient series have been relatively small. We therefore estimated the genotypes for FHR1 and FHR3 gene deletion in paediatric aHUS patients either with (n = 96) or without (n = 68) anti-FH autoantibodies, and compared them with aHUS patient family members (n = 65) and unrelated healthy adult volunteers (n = 84), as reported earlier. 8 As expected, aHUS patients with anti-FH autoantibodies were homozygous for FHR1 and FHR3 deletion with very high frequencies (Table 2) . However, even patients with no detectable anti-FH autoantibodies were homozygous for FHR1 and FHR3 deletion with frequencies higher than those in healthy volunteers (Table 2 ; P < 0Á02), suggesting the possibility (subject to caveats explored below) that the homozygous FHR1-3-deletion genotype may also make some contribution to aHUS through anti-FH autoantibody-independent pathways. 
FH-containing immune complexes are not detected in anti-FH autoantibody-negative aHUS patients
As the frequency of homozygous FHR1 and FHR3 deletion in paediatric aHUS patients with no anti-FH autoantibodies appeared to be high, it was necessary to examine if these patients simply had levels of anti-FH autoantibodies too low to be detected in the assay used. The quantified levels of anti-FH autoantibodies were not different between the two groups (Fig. 1a) . Nonetheless, even in the absence of free detectable anti-FH antibodies, FH-containing immune complexes would be expected to be present. We therefore tested some sera from four patient groups, with or without either FHR1 deletion and/or anti-FH autoantibodies, for FH-containing immune complexes. However, those tested patients who did not show detectable free anti-FH autoantibodies did not show detectable FH-containing immune complexes either, regardless of their genotype ( Fig. 1d and e) . As expected, patients with free anti-FH antibodies also showed strong signals for FH-containing immune complexes ( Fig. 1a and b) . The epitope recognized by the plate-coated MCA509G monoclonal antibody, secreted by the OX-24 clone, involves SCR5 of FH. 34 Although some interference of MCA509G with FH-bound autoantibodies may occur, it is unlikely that it would shift FH from the immune complex state to the free state. This possibility is supported by the fact that FH-immune complex assays using either MCA509G or a polyclonal anti-FH antibody did not show any differences, indicating that displacement of bound autoantibody by the plate-coated anti-FH antibodies was unlikely to be a major concern for assay validity. Hence, these data further supported the possibility that the homozygous FHR1-3-deletion genotype may make some modest contribution to the pathogenesis of aHUS through anti-FH autoantibody-independent pathways.
Analysis of epitope specificity and avidity of anti-FH autoantibodies
We next examined the epitope specificity of serum anti-FH autoantibodies in paediatric aHUS patients homozygous for deletion of FHR1 and FHR3 genes. Five recombinant FH fragments, FH-SCR1-4, FH-SCR5-8, FH-SCR9-12, FH-SCR13-16 and FH-SCR17-20, were used. The relative sizes of these fragments were as expected (see Supplementary material, Fig. S1 ). We chose to use inhibition ELISAs with these fragments to ensure detection and analysis of native FH-relevant antibodies and to provide definitive evidence for cross-reactivity where appropriate. The binding of anti-FH autoantibodies in the reference pool of patient sera to native solid-phase FH was not detectably inhibited by FH-SCR1-4, FH-SCR9-12, or FH-SCR13-16 (Fig. 2a) . Aqueous-phase native FH inhibited binding well as expected, and the C-terminal fragment, FH-SCR17-20, inhibited FH-binding of serum autoantibodies well, with an IC 50 value (0Á1 lM) higher than that for native FH (0Á21 lM) (Fig. 2a) . Notably, FH-SCR5-8 also substantially inhibited anti-FH autoantibody binding to native FH, albeit at lower relative avidity (1Á17 lM) (Fig. 2a) .
This raised the possibility that anti-FH autoantibodies in aHUS sera were cross-reactive between FH-SCR17-20 and FH-SCR5-8. We tested this by using the FH-SCR-17-20 fragment as the solid-phase, and using native FH, FH-SCR17-20, or FH-SCR5-8 to inhibit the binding of autoantibodies in the pool of aHUS patient sera. Once again, aqueous-phase native FH inhibited binding to FH-SCR17-20, as did FH-SCR17-20 itself, with comparable efficiency (Fig. 2b) . Further, FH-SCR5-8 also efficiently inhibited autoantibody binding to FH-SCR17-20, although with lower efficiency (Fig. 2b) . Hence, the bulk of anti-FH autoantibodies in a pool of aHUS patient sera recognized FH-SCR17-20 with high affinity and crossreacted with FH-SCR5-8 at low affinity.
Epitope specificity and avidity of anti-FH autoantibodies in paediatric aHUS patients
We next examined the epitope specificities of anti-FH autoantibodies in aHUS patients, both in those who were homozygous for FHR1 and FHR3 deletion (n = 15) and in those who did not show this deletion genotype (n = 6). In the majority of instances of both genotypes, high concentrations of either native FH or FH-SCR17-20 caused over 80% inhibition of binding to solid-phase native FH (Fig. 3a) . High concentration of FH-SCR5-8 also led to over 60% inhibition in most instances (Fig. 3a) . Lower inhibitor concentrations led to variable reductions in solid-phase FH binding (Fig. 3a) , indicating variable anti-FH autoantibody avidity. Relative avidities, as indicated by the slopes of the lines defined by the two concentrations used of each inhibitor tested, did not differ between the patient groups that were or were not homozygous for FHR1 and FHR3 deletion (Fig. 3b) . The anti-FH autoantibody levels were well-correlated with the extent of inhibition observed at a given inhibitor concentration (Fig. 3c-e) , indicating that higher autoantibody levels were associated with higher avidity. Native FH, SCR17-20 and SCR5-8 were well correlated with each other with regard to the extent of inhibition caused in all sera tested (Fig. 3f-h) , further suggesting the prominence of antibodies recognizing the cross-reactive epitopes on SCR17-20 and SCR5-8.
We also looked for indications of correlations, if any, between epitope specificity and avidity of anti-FH autoantibodies and clinical patterns in 20 of these patients with a median age of 8Á8 years (range 6Á5-10 years). In this small group of patients, the avidity or epitope specificity did not show any significant associations with disease severity (haemoglobin, platelet count, serum creatinine, duration of oliguria, serum lactate dehydrogenase) or adverse outcomes, or between patients with (n = 6) or without (n = 14) relapse.
Discussion
We have attempted to probe some of the puzzles regarding aHUS using a series of paediatric aHUS patients. Using qPCR and PCR approaches to detecting the homozygous 83-kb deletion encompassing FHR1 and FHR3 genes in a large paediatric aHUS series, we find that the deletion is modestly but clearly over-represented even in aHUS patients that have no detectable anti-FH autoantibodies or immune complexes, suggesting possible anti-FH autoantibody-independent pathways connecting the deletion to aHUS. We have characterized anti-FH autoantibody affinities and epitope specificities, and find highly variable affinities and relatively conserved epitope specificities for the C-terminus of FH. However, we also find that these C-terminal-specific anti-FH autoantibodies also cross-react at low affinity with the mid-portion of the FH molecule, suggesting possible pathways for anti-FH autoantibody-mediated modulation of FH function.
Although MLPA is currently used as the reference standard for detection of the FHR1-FHR3 deletion, we found that the optimized qPCR detected both homozygous and heterozygous genotypes equally well. In fact, a simple in-gel PCR assay for FHR1 detected the homozygous genotype quite reliably. Together, these PCR-based assays may well be of use for easier detection of the FHR1-FHR3 deletion.
The FHR1-FHR3 deletion has been classically reported to be associated with the anti-FH autoantibody-positive form of aHUS, 1, 36 although there has been some indication of occasional aHUS patients with the FHR1-FHR3 deletion but without anti-FH autoantibodies. 6 Our data, based on substantial numbers of both anti-FH autoantibody-positive and -negative aHUS patients, provide evidence that FHR1-FHR3 deletion also occurs in anti-FH autoantibody-negative aHUS at a higher frequency than that in the normal population. It is well recognized that the FHR1-FHR3 deletion occurs in the healthy population as a polymorphism. 3 In our population,~9% of healthy individuals (without aHUS) had a homozygous FHR1-FHR3 deletion, whereas~20% of anti-FH antibody-negative aHUS patients and~75% of anti-FH antibody-positive aHUS patients had a homozygous FHR1-FHR3 deletion. One possibility was that the lack of detection of anti-FH autoantibodies in at least some of these aHUS patients could be a consequence of low antibody levels that were mostly bound to circulating FH, leading to antibody-mediated modulation of FH function in the absence of detectable anti-FH antibodies. We examined this possibility by assaying for FH-containing immune complexes. However, we were unable to detect such immune complexes in the sera of anti-FH antibodynegative aHUS patients homozygous for the FHR1-FHR3 deletion. As the epitope recognized by the plate-coated MCA509G monoclonal antibody involves FH-SCR5, 34 and the major anti-FH autoantibodies in our patient series do cross-react with FH-SCR5-8, our data show that those antibodies also bind with higher avidity to FH-SCR17-20, suggesting that interference of MCA509G with FH-bound autoantibodies is unlikely to shift FH from the immune complex state to the free state, consistent with the fact that FH-immune complex assays using either MCA509G or a polyclonal anti-FH antibody did not show any differences.
These data suggest that the FHR1-FHR3 deletion can also predispose to paediatric aHUS via additional pathways independent of the known major pathway of a break of FH-specific B-cell tolerance. Whether such an aHUS sub-group has additional risk factors and/or distinct clinical behaviours needs to be explored.
In the present data, we have not explored the presence of a number of other mutations in complement-related genes that are known in HUS, including the genes for FH and monocyte chemoattractant protein 37, 38 Hence, it is possible that the anti-FH-negative aHUS patients associated with the modest increase of FHR1-FHR3 deletion that we observe are in fact, related to the presence of such mutations, although this would still not explain the increased frequency of the FHR1-FHR3 deletion in such sub-groups.
It is noteworthy that the FHR1-FHR3 deletion is also associated in various ways with other anti-FH autoantibody-independent immuno-inflammatory diseases such as systemic lupus erythematosus, 4 IgA nephropathy 5 and age-related macular degeneration. 27 Also, the FHR1-FHR3 deletion is not sufficient in itself to give rise to long-lasting anti-FH autoantibodies, as evidenced by the wide prevalence of this deletion without concomitant anti-FH antibodies in healthy populations. 3 Together, these data suggest that it is necessary to examine immunomodulation by the FHR1-FHR3 deletion in both FH-specific and more general ways.
Anti-FH autoantibodies in aHUS patients have also been shown to cross-react with C-terminal regions of FHR1, 8 although the functional significance of this finding in human disease is unclear because these anti-FH autoantibodies are associated with a homozygous FHR1-FHR3 deletion genotype.
In addition to socio-geographic settings, our series of paediatric aHUS patients differs from other reports in terms of the high prevalence of anti-FH autoantibodypositive patients. 7 We therefore sought to characterize the anti-FH antibodies in these patients in further detail. Although most previous studies have identified the C-terminus of FH to be the binding site for aHUSassociated anti-FH autoantibodies, 8, 10, 11 there have been reports of recognition of the N-terminal and central regions of FH as well. 11 Our data show that anti-FH autoantibodies in Indian paediatric aHUS patient sera dominantly if not exclusively recognize the C-terminal SCR17-20 region of FH. Notably, although our data show the presence of sero-reactivity to the mid-region SCR5-8 of FH, we find that most autoantibodies binding to FH-SCR5-8 are those that bind to the C-terminal SCR17-20. In fact, the affinity of these autoantibodies to FH-SCR5-8 is uniformly lower than their affinity to FH-SCR17-20. Hence, FH-SCR17-20 is likely to be the dominant immunogenic epitope for anti-FH autoantibodies in paediatric aHUS.
Interestingly, FH-SCR19-20 and SCR6-8 are reported to be involved in binding to cell surface glycoproteins. 13 Anti-FH antibodies are known to have functional consequences; they block binding of factor H to cell surfaces and hence affect complement regulation. 10 FH functions to regulate complement activity both in the fluid phase and on cell surfaces. 15, 37 In fact, a complete deletion of the FH gene and function in mice leads to membranoproliferative glomerulonephritis 19 whereas partial complementation with a C-terminal-deficient fluid-phase active form of HUS in these mice changes the disease to an HUS-like syndrome. In this context, the dominance of anti-FH autoantibodies directed in cross-reactive fashion to the cell-surface anchorage regions of FH that we find may be particularly relevant.
Autoimmune antibody-mediated disease pathogenesis for some target antigens has been correlated with antibody affinity, although such associations have been variably observed. 39, 40 For some autoantigens and autoantibodies, the immune complexes themselves deposit in glomeruli and contribute to disease, 12, 16, 18 and low-affinity antibodies may generate persistently circulating immune complexes. 41, 42 This is not likely to be relevant for aHUS, as there is no evidence of immune complex deposition contributing to the disease. 6 Other autoimmune targets, such as the acetylcholine receptor, are cell-surface molecules, and effective binding may be achieved despite low antibody affinity. In this context, we were interested to investigate the possible roles that anti-FH autoantibody affinity may play in aHUS, and we now show an assay for both FH-specific and epitope-specific relative affinity. Using this assay, we find a wide variety of average relative affinities in the anti-FH autoantibodies, and autoantibody concentrations do not correlate with affinities. These assays now enable the future examination of whether clinical parameters in aHUS show any associations with either affinity and/or with epitope specificities of anti-FH autoantibodies. These will be critical issues in understanding the complex connections between FHR1/3 deletion and immuno-inflammatory diseases. nology are funded by grants-in-aid from the DBT, GoI. None of the funding sources had any involvement in study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the article for publication. BSG and AB performed experiments, analysed the data, and helped write the manuscript. TMS, SB and MP developed critical tools and analysed data. MS and SS developed critical methodologies and helped collect the data. PK, AS, PH and AB conceptualized the approach, did the critical clinical components of the work, supervised the data collection, and analysed the data. AKV, PC and PG provided crucial conceptual inputs. VB, AG, SR, AS and AB conceptualized the approach, designed the experiments, analysed the data, and wrote the manuscript. All authors read, edited and approved the final manuscript.
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